Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies

• Published in: Leukemia & lymphoma Vol. 63; no. 10; pp. 2413 - 2421
• Main Authors: Landgren, Ola, Kazandjian, Dickran, Roussel, Murielle, Jasielec, Jagoda, Dytfeld, Dominik, Anderson, Aparna, Kervin, Tara A., Iskander, Karim, McFadden, Ian, Jakubowiak, Andrzej J.
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 24.08.2022
• Subjects: Antineoplastic Combined Chemotherapy Protocols - adverse effects; clinical trials; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone - therapeutic use; Humans; Lenalidomide - therapeutic use; Melphalan - therapeutic use; Multiple Myeloma - drug therapy; newly diagnosed multiple myeloma; Oligopeptides - therapeutic use; Proteasome inhibitors; newly diagnosed multiple myeloma; clinical trials; Proteasome inhibitors
• ISSN: 1042-8194; 1029-2403; 1029-2403
• DOI: 10.1080/10428194.2022.2068001

Pooled analyses of four single-arm phase 1 and 2 studies (NCT01816971, NCT02405364, NCT01029054, NCT01402284) investigated the clinical effectiveness of carfilzomib-lenalidomide-dexamethasone (KRd) in newly diagnosed multiple myeloma (NDMM). Patients who did (Cohort 1; n = 122) and did not (Cohort 2; n = 99) undergo autologous stem cell transplant (high-dose melphalan [HDM]-ASCT) were included. Patients received a 28-day cycle of induction KRd. The rate of very good partial response or better, the primary endpoint, was 93% in Cohort 1 and 90% in Cohort 2. Two-year progression-free survival and overall survival rates were 88% and 96% for Cohort 1, and 85% and 97% for Cohort 2. At least 90% of patients in each cohort reported ≥1 grade 3 or 4 treatment-emergent adverse events. Subgroup analyses by age, International Staging System stage, and cytogenetic risk were consistent with the overall population. KRd is an effective and tolerable treatment option for patients with NDMM regardless of HDM-ASCT eligibility.